More than 20 years have passed since the seminal report that simvastatin reduced cardiovascular event rates in survivors of myocardial infarction. This was followed by a large number of clinical trials that reinforced the importance of lipid lowering, with statins becoming the cornerstone for cardiovascular prevention. However, the finding that many cardiovascular events continue to occur despite statin therapy 1 highlights the need to develop additional approaches that will complement statin therapy and result in more effective reduction of cardiovascular risk.
The evolving paradigm of pathological events promoting the formation, progression and rupture of atherosclerotic plaque have provided important insights with the potential to inform what are the next targets for therapeutic modulation. These studies have emphasised the importance of atherogenic lipoproteins and inflammatory pathways in promoting atherosclerosis and a potentially protective role for high-density lipoproteins (HDL). The finding that circulating biomarkers related to these factors associate with the residual clinical risk observed in statin-treated patients provided further support for the development of new therapies. However, the disappointing results of clinical trials of fibrates, HDL raising agents and anti-inflammatory therapies have failed to produce new agents in clinical practice.
In the current issue of the journal, Gregson and colleagues report their investigation of the relationship of loss of function variants in lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ) and cardiovascular risk in more than 300,000 individuals from a range of observational studies. 2 They reported that loss of function variants were associated with a 45% reduction in Lp-PLA 2 activity per inherited allele, but no reduction in cardiovascular risk. This paralleled their observations that the chemical Lp-PLA 2 inhibitor, darapladib, reduced activity by 65%, yet similarly produced no cardiovascular benefit in two large clinical outcomes trials. 3, 4 They concluded that Lp-PLA 2 is unlikely to be a causal risk factor for atherosclerosis and questioned whether chemical inhibition would be a viable anti-atherosclerotic strategy.
The rationale for clinical development was based on pathology observations that implicated Lp-PLA 2 in atherosclerosis. Lp-PLA 2 is present within unstable plaques and plays an important role in the generation of bioactive products of arachidonic acid metabolism that promote a range of inflammatory and oxidative pathways. 5 Development of darapladib as a chemical Lp-PLA 2 inhibitor received early enthusiasm on the basis of favourable effects on a porcine model of atherosclerosis 6 and in an early intravascular imaging study in patients with coronary disease demonstrating a protective influence on expansion of the necrotic core, a secondary endpoint. 7 These data were supported by observational data from the same authors as the present genetic study that circulating Lp-PLA 2 levels were as strongly associated with coronary heart disease as LDL-C. 8 This latter finding in particular persuaded the drug developer to conduct two large clinical outcomes studies of darapladib in patients with stable and unstable ischaemic syndromes. However, the inability of darapladib to reduce cardiovascular events in both studies suggests that the inhibition of Lp-PLA 2 is unlikely to be cardioprotective.
The findings of Gregson and colleagues reinforce the trial data and further dampen enthusiasm for Lp-PLA 2 inhibition as a causal factor in atherosclerosis. 2 The alignment of the genetic invalidation of Lp-PLA 2 with the lack of efficacy of darapladib in outcome trials raises the intriguing question regarding the utility of genetic analyses in drug development. Advances in genetic sequencing of very large cohorts now enable the study of genetic polymorphisms associated with a range of chronic diseases. This is particularly important in processes such as atherosclerosis, which reflect the outcome of multiple genetic, environmental and metabolic influences on the artery wall. While there is no single gene underlying atherosclerosis, genetic studies to date have revealed an abundant number of polymorphisms influencing cardiovascular risk, whether studied individually or combined to create genetic scores.
The more recent application of Mendelian randomisation studies permits unconfounded evaluation of a natural distribution to normal and mutant genes within large populations to determine whether their impact on established cardiovascular biomarkers correlates with predictable changes in clinical events. Such studies have reaffirmed the low-density lipoprotein (LDL) hypothesis by demonstrating that mutations of both proprotein convertase subtilisin kexin type 9 (PCSK9) and 3-hydroxy-methylglutaryl coenzyme A reductase associate with lower levels of cardiovascular risk, which correlate with their degree of reduction of LDL cholesterol. 9 In contrast, the lack of association between polymorphisms regulating HDL cholesterol and cardiovascular risk parallels the failure of any HDL raising agent to reduce event rates in contemporary clinical trials. 10 These findings do raise the provocative question of what role genetic analyses should play in drug development? Given the additional layer of causative evidence played by genetic studies in identifying factors that play important roles in promoting cardiovascular risk, are these the factors that should primarily be the focus for targeting with new agents? Findings that genetic mutations altering triglyceride-rich lipoprotein and lipoprotein (a) levels support the development of agents targeting apolipoprotein C-III, angiopoiten-like proteins and apolipoprotein (a). 11, 12 The ability to demonstrate that these agents would reduce clinical events will ultimately be required to validate the potential for genetic studies to guide drug development.
To what degree these studies can inform on the patient cohort most likely to benefit is uncertain. While the genetic studies have been performed on very large cohorts extending across a broad range of cardiovascular risk, phase 3 clinical outcome trials have traditionally been performed in relatively narrow cohorts such as acute coronary syndromes, stable coronary disease or high-risk primary prevention. Whether additional factors exist in the context of clinical trials that potentially limit generalisability to broader populations cannot be estimated by genetic studies is unknown. Alternatively, genetic analyses may potentially identify patients most likely to benefit from cardioprotective agents. While the modest cholesteryl ester transfer protein (CETP) inhibitor, dalcetrapib, failed to reduce cardiovascular events in a large study in patients with a recent acute coronary syndrome, 13 a post hoc pharmacogenomic analysis reported potentially favourable effects on cholesterol efflux, inflammatory markers, carotid intima-medial thickness and cardiovascular events in patients harbouring a polymorphism of the ADCY9 gene on chromosome 16. 14 This finding has informed a subsequent clinical trial that is currently evaluating the impact of dalcetrapib in patients possessing this polymorphism. While this may reflect the start of a pharmacogenomics approach to drug development, this will ultimately require validation by demonstrating dalcetrapib efficacy.
Will pharmacogenomics limit the need to perform extraordinarily large and expensive phase 3 clinical trials? Will it be possible to perform more targeted proof of concept studies in order to bring new agents to the clinic more efficiently? This seems unlikely, given the need to evaluate the safety of these agents comprehensively to evaluate both on and off-target effects and to determine their cost effectiveness. Regardless of this, we may now have an important additional approach to help us address the residual risk in our patients. While genetic studies may improve the efficiency of the drug development process, clinical trials will remain the cornerstone for providing conclusive evidence of both efficacy and safety required to inform global clinical guidelines.
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